The Call of Duty League Super Week continues tonight with day four, and three more matches. Here’s our preview of tonight’s matches.
Minnesota Rokkr vs New York Subliners
Minnesota Rokkr currently sit with a 2-1 record in the 2021 CDL Season. They have continued to excel in Search and Destroy with a 4-0 win rate, and are favourites to win this matchup. However, this may be another “steal a respawn win the series” affair.
New York Subliners on the other hand started off slow, but have turned it around after defeating the London Royal Ravens earlier in the week. This will be a tough match, however if Asim can perform how he did against the Ravens, they could take all three respawns and win the map.
We’re looking at Minnesota to win both Search and Destroys, while winning one other respawn map to take the series 3-2. Therefore, we’re backing Map 2 ML and Match ML.
Pick: Minnesota Rokkr Map 2 ML, 1.60 @ Betway & Minnesota Rokkr ML, 1.50 @ Betway
OpTic Chicago vs Los Angeles Guerrillas
OpTic Chicago clutched up against the Toronto Ultra, winning the series 3-1. This was an essential match win following their defeat to Atlanta FaZe, however this match shouldn’t be much of an issue.
Los Angeles Guerrillas suffered a defeat to the Florida Mutineers, putting them 1-2 in the group so far. Their only chance to take this series is in the Search and Destroy, however we think that OpTic will be clinical in the respawns, and take the series 3-1 or 3-0.
Pick: OpTic Chicago -1.5, 1.45 @ Betway & OpTic Chicago Map 3 ML, 1.30 @ Betway
Atlanta FaZe vs Florida Mutineers
This match is looking like the best of the night, with two top teams going head to head. While Florida defeated Atlanta FaZe in the Kickoff Classic, a lot has changed since. Florida suffered a 3-0 defeat to Paris Legion, and have thus drastically dropped down our power rankings. However, FaZe look clinical in Search and Destroy and Control, leaning us towards a 3-0/3-1 win for FaZe.
For this match, we’re backing FaZe -1.5. This is because we’re not convinced by Florida just yet, and FaZe have looked clinical recently.